11 results on '"Joseph, Mano"'
Number of results to display per page
Search Results
2. Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies
- Author
-
Shah, Manish A., primary, Udrea, Anghel Adrian, additional, Bondarenko, Igor, additional, Mansoor, Was, additional, Sánchez, Raquel Guardeño, additional, Sarosiek, Tomasz, additional, Bozzarelli, Silvia, additional, Schenker, Michael, additional, Gomez-Martin, Carlos, additional, Morgan, Carys, additional, Özgüroğlu, Mustafa, additional, Pikiel, Joanna, additional, Kalofonos, Haralabos P., additional, Wojcik, Elzbieta, additional, Buchler, Tomas, additional, Swinson, Daniel, additional, Cicin, Irfan, additional, Joseph, Mano, additional, Vynnychenko, Ihor, additional, Luft, Alexander Valerievich, additional, Enzinger, Peter C., additional, Salek, Tomas, additional, Papandreou, Christos, additional, Tournigand, Christophe, additional, Maiello, Evaristo, additional, Wei, Ran, additional, Ferry, David, additional, Gao, Ling, additional, Oliveira, Joana M., additional, and Ajani, Jaffer A., additional
- Published
- 2022
- Full Text
- View/download PDF
3. Adverse Drug Reactions As Cause Of Admission To Hospital
- Author
-
Williams, Edwina R. L., Taylor, Ruth E., Saunders, Daniel J., Laws, M. Barton, Joseph, Mano, Calder, Nicholas J., MacDonald, Duncan, Pirmohamed, Munir, James, Sally, Meakin, Shaun, and Green, Chris
- Published
- 2004
4. Optimising Chemotherapy for Frail and Older Patients With Advanced Gastroesophageal Cancer: The GO2 Phase III Trial
- Author
-
Mohammed Abdul Imran Khan, Tania Tillett, Rajarshi Roy, Simon Lord, Zuzana Stokes, Helen Howard, Matthew T. Seymour, Christine Allmark, C. Handforth, Guptal Kamalnayan, Jonathan Nicoll, Eszter Katona, Joseph Mano, Sharon Ruddock, Nick Maisey, David A Cairns, Galina Velikova, Ángel David Roncancio García, Jonathan Wadsley, Anirban Chatterjee, Peter Hall, Daniel Swinson, Stephen Falk, Pei Loo Ow, Helen Marshall, Simon Grumett, Sebastian Cummins, Heike I. Grabsch, Jo Dent, Kamposioras Kostantinos-Vellios, Justin Waters, Russell D. Petty, Anne Crossley, and Thomas K. Waddell
- Subjects
medicine.medical_specialty ,business.industry ,Combination chemotherapy ,Oxaliplatin ,Capecitabine ,Regimen ,Geriatric oncology ,Internal medicine ,medicine ,Dosing ,Outcomes research ,business ,medicine.drug ,Epirubicin - Abstract
Background: GO2 sought to optimise chemotherapy dosing in older/frail patients with advanced gastroesophageal cancer, and explored baseline geriatric assessment (GA) as a tool for treatment decision-making. Methods: Patients were recruited for whom full-dose combination chemotherapy was considered unsuitable. Two randomisation options were available: CHEMO-INTENSITY compared oxaliplatin/capecitabine at Level A (doses as used in the standard epirubicin/oxaliplatin/capecitabine regimen), B (0·8x A) or C (0·6x A). Non-inferiority of PFS was assessed using boundary HR=1·34, selected by a forum of patients and clinicians. Overall Treatment Utility (OTU), which combines efficacy, toxicity, QL and patient value/acceptability, was scored at nine weeks. Alternatively, if the patient and clinician agreed the indication for chemotherapy was uncertain, they could enter the CHEMO-BSC randomisation, comparing Level C versus best supportive care. Findings: 514 patients entered the CHEMO-INTENSITY randomisation: non-inferior PFS was confirmed for B vs A (HR=1·09 [CI=0·89-1·32]) and C vs A (HR=1·10 [0·90-1·33]). Level C produced less toxicity and better OTU than A or B. No subgroup benefited from higher doses: Level C produced better OTU even in the younger, fitter patients. 45 patients entered the CHEMO-BSC randomisation: overall survival was non-significantly longer with chemotherapy: median 6·1 vs 3·0 months, HR=0·69 [0·32-1·48], p=0·34. In multivariate analysis, baseline frailty, QL and neutrophil:lymphocyte ratio were independently associated with OTU, so can be combined in a model to estimate the probability of better or worse outcome. Interpretation: Reduced-intensity chemotherapy provided non-inferior efficacy with an improved patient experience. Baseline geriatric assessment can help predict the utility of chemotherapy. Trial Registration: [Trial registration: ISRCTN44687907] Funding Statement: Cancer Research UK [CRUK/12/022] Declaration of Interests: Dr. Grabsch reports personal fees from Merck Sharpe Dome, outside the submitted work; all other authors have nothing to declare. Ethics Approval Statement: This study was approved by the UK National Research Ethics Service and overseen by independent Trial Steering and Data Monitoring & Ethics Committees (TSC; IDMC).
- Published
- 2020
5. Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer
- Author
-
Pei Loo Ow, Angel Garcia, Lesley Samuel, Rajarshi Roy, Adam McGeoch, D. Fyfe, W Saku, Simon Aird Grumett, Jonathan Nicoll, Jo Dent, Tom Samuel Waddell, Jo Webster, Christine Allmark, Tania Tillett, Colin Askill, Justin S. Waters, C. Handforth, Erica Beaumont, Vallipuram Vigneswaran, Sharon Ruddock, Nick Wadd, Syed Zubair, Kinnari Patel, Vanessa Potter, Daniel Propper, Olwyn Williams, Marc Jones, Kamalnayan Guptal, Peter Hall, Gareth Griffiths, Joseph Mano, Juan W. Valle, Sheela Rao, David A Cairns, Go Trial Investigators, Eszter Katona, Nick Maisey, Chris Twelves, Daniel Swinson, Nicholas Reed, Heike I. Grabsch, Joanne Askey, Jonathan Wadsley, Tom Roques, Sue Cheeseman, Stephen Falk, Louise Medley, Arshad Jamil, Emma Cattell, Victori Kunene, Matthew R. Sydes, Charles Candish, Claire Hobbs, Rebecca Herbertson, Jo Parkinson, Nicholas S. Reed, Louise Brook, Zuzana Stokes, Mohammed Khan, Ann Crossley, Elin Jones, George Bozas, Sebastian Cummins, Anirban Chatterjee, Michael Bennet, Helen Marshall, Pavel Bezecny, David Sherriff, Matthew T. Seymour, Lauren Gorf, Galina Velikova, Jean Gall, Kamposioras Konstantinos-Velios, Sally Clive, Eleanor James, Fiona Collinson, Dunca Wilkins, Simon Lord, Julia Brown, Serena Hilman, A. Robinson, Richard Ellis, Alaaeldin Shablak, Russell D Petty, Sherif Raouf, Helen Howard, RS: GROW - R2 - Basic and Translational Cancer Biology, and Pathologie
- Subjects
Cancer Research ,medicine.medical_specialty ,Randomization ,EUROPEAN-ORGANIZATION ,law.invention ,II TRIAL ,Capecitabine ,ESOPHAGOGASTRIC JUNCTION ,03 medical and health sciences ,REGRESSION-MODELS ,0302 clinical medicine ,Randomized controlled trial ,Quality of life ,law ,Internal medicine ,medicine ,030212 general & internal medicine ,ELDERLY-PATIENTS ,ADVANCED GASTRIC-CANCER ,business.industry ,Hazard ratio ,ADENOCARCINOMA ,Combination chemotherapy ,Chemotherapy regimen ,FLUOROURACIL ,Oxaliplatin ,METASTATIC COLORECTAL-CANCER ,Oncology ,030220 oncology & carcinogenesis ,1ST-LINE THERAPY ,business ,medicine.drug - Abstract
Importance: Older and/or frail patients are underrepresented in landmark cancer trials. Tailored research is needed to address this evidence gap. Objective: The GO2 randomized clinical trial sought to optimize chemotherapy dosing in older and/or frail patients with advanced gastroesophageal cancer, and explored baseline geriatric assessment (GA) as a tool for treatment decision-making. Design, Setting, and Participants: This multicenter, noninferiority, open-label randomized trial took place at oncology clinics in the United Kingdom with nurse-led geriatric health assessment. Patients were recruited for whom full-dose combination chemotherapy was considered unsuitable because of advanced age and/or frailty. Interventions: There were 2 randomizations that were performed: CHEMO-INTENSITY compared oxaliplatin/capecitabine at Level A (oxaliplatin 130 mg/m 2on day 1, capecitabine 625 mg/m 2twice daily on days 1-21, on a 21-day cycle), Level B (doses 0.8 times A), or Level C (doses 0.6 times A). Alternatively, if the patient and clinician agreed the indication for chemotherapy was uncertain, the patient could instead enter CHEMO-BSC, comparing Level C vs best supportive care. Main Outcomes and Measures: First, broad noninferiority of the lower doses vs reference (Level A) was assessed using a permissive boundary of 34 days reduction in progression-free survival (PFS) (hazard ratio, HR = 1.34), selected as acceptable by a forum of patients and clinicians. Then, the patient experience was compared using Overall Treatment Utility (OTU), which combines efficacy, toxic effects, quality of life, and patient value/acceptability. For CHEMO-BSC, the main outcome measure was overall survival. Results: A total of 514 patients entered CHEMO-INTENSITY, of whom 385 (75%) were men and 299 (58%) were severely frail, with median age 76 years. Noninferior PFS was confirmed for Levels B vs A (HR = 1.09 [95% CI, 0.89-1.32]) and C vs A (HR = 1.10 [95% CI, 0.90-1.33]). Level C produced less toxic effects and better OTU than A or B. No subgroup benefited from higher doses: Level C produced better OTU even in younger or less frail patients. A total of 45 patients entered the CHEMO-BSC randomization: overall survival was nonsignificantly longer with chemotherapy: median 6.1 vs 3.0 months (HR = 0.69 [95% CI, 0.32-1.48], P =.34). In multivariate analysis in 522 patients with all variables available, baseline frailty, quality of life, and neutrophil to lymphocyte ratio were independently associated with OTU, and can be combined in a model to estimate the probability of different outcomes. Conclusions and Relevance: This phase 3 randomized clinical trial found that reduced-intensity chemotherapy provided a better patient experience without significantly compromising cancer control and should be considered for older and/or frail patients. Baseline geriatric assessment can help predict the utility of chemotherapy but did not identify a group benefiting from higher-dose treatment. Trial Registration: isrctn.org Identifier: ISRCTN44687907.
- Published
- 2021
6. Adverse drug reactions as cause of admission to hospital: Only part of the picture was reported for aspirin
- Author
-
Joseph, Mano
- Published
- 2004
7. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV) : an open-label randomised controlled phase 3 trial
- Author
-
Mehanna, Hisham M., Robinson, Max, Hartley, Andrew, Kong, Anthony, Foran, Bernadette, Fulton-Lieuw, Tessa, Dalby, Matthew, Mistry, Pankaj, Sen, Mehmet, O'Toole, Lorcan, Al Booz, Hoda, Dyker, Karen, Moleron, Rafael, Whitaker, Stephen, Brennan, Sinéad, Cook, Audrey, Griffin, Matthew, Aynsley, Eleanor, Rolles, Martin, De Winton, Emma, Chan, Andrew, Srinivasan, Devraj, Nixon, Ioanna, Grumett, Joanne, Leemans, C René, Buter, Jan, Henderson, Julia, McConkey, Christopher C., Gray, Alastair, Dunn, Janet A., McArdle, Orla, Husband, David, Loo, Vivienne, Soe, Win, Sridhar, Thiagarajan, Jankowska, Petra, Joseph, Mano, Geropantas, Konstantinos, Vaidya, Deepali, Vijayan, Rengarajan, Hwang, David, Harrington, Kevin, Pettit, Laura, Mendes, Ruheena, Forster, Martin, Evans, Mererid, Nankivell, Paul, Bryant, Jennifer, Sharma, Neil, Spruce, Rachel, Brooks, Jill, Batis, Nikos, Roques, Tom, Bidmead, Margaret, Yang, Huiqi, Nutting, Christopher, Tyler, Justine, Baines, Helen, Gasnier, Anne, Miles, Elizabeth, and Clark, Catharine
- Subjects
RC0254 ,RM - Abstract
Background\ud \ud The incidence of human papillomavirus (HPV)-positive oropharyngeal cancer, a disease affecting younger patients, is rapidly increasing. Cetuximab, an epidermal growth factor receptor inhibitor, has been proposed for treatment de-escalation in this setting to reduce the toxicity of standard cisplatin treatment, but no randomised evidence exists for the efficacy of this strategy.\ud \ud Methods\ud \ud We did an open-label randomised controlled phase 3 trial at 32 head and neck treatment centres in Ireland, the Netherlands, and the UK, in patients aged 18 years or older with HPV-positive low-risk oropharyngeal cancer (non-smokers or lifetime smokers with a smoking history of
- Published
- 2018
8. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- Author
-
Cohen, Ezra E W, primary, Soulières, Denis, additional, Le Tourneau, Christophe, additional, Dinis, José, additional, Licitra, Lisa, additional, Ahn, Myung-Ju, additional, Soria, Ainara, additional, Machiels, Jean-Pascal, additional, Mach, Nicolas, additional, Mehra, Ranee, additional, Burtness, Barbara, additional, Zhang, Pingye, additional, Cheng, Jonathan, additional, Swaby, Ramona F, additional, Harrington, Kevin J, additional, Acosta-Rivera, Mirelis, additional, Adkins, Douglas R., additional, Aghmesheh, Morteza, additional, Airoldi, Mario, additional, Aleknavicius, Eduardas, additional, Al-Farhat, Yousuf, additional, Algazi, Alain P., additional, Almokadem, Salah, additional, Alyasova, Anna, additional, Bauman, Jessica R., additional, Benasso, Marco, additional, Berrocal, Alfonso, additional, Bray, Victoria, additional, Burtness, Barbara Ann, additional, Caponigro, Francesco, additional, Castro, Ana, additional, Cescon, Terrence P., additional, Chan, Kelvin, additional, Chaudhry, Arvind, additional, Chauffert, Bruno, additional, Cohen, Ezra, additional, Csoszi, Tibor, additional, De Boer, J.P., additional, Delord, Jean-Pierre, additional, Dietz, Andreas, additional, Dinis, Jose, additional, Dupuis, Charlotte, additional, Digue, Laurence, additional, Erfan, Jozsef, additional, Escobar Alvarez, Yolanda, additional, Evans, Mererid, additional, Fidler, Mary Jo, additional, Forster, Martin David, additional, Friesland, Signe, additional, Ganti, Apar K., additional, Geoffrois, Lionnel, additional, Grant, Cliona, additional, Gruenwald, Viktor, additional, Harrington, Kevin, additional, Hoffmann, Thomas, additional, Horvai, Geza, additional, Inciura, Arturas, additional, Jang, Raymond, additional, Jankowska, Petra, additional, Jimeno, Antonio, additional, Joseph, Mano, additional, Juarez Ramiro, Alejandro, additional, Karaszewska, Boguslawa, additional, Kawecki, Andrzej, additional, Keilholz, Ulrich, additional, Keller, Ulrich, additional, Kim, Sung-Bae, additional, Kocsis, Judit, additional, Kotecki, Nuria, additional, Kozloff, Mark F., additional, Lambea, Julio, additional, Landherr, Laszlo, additional, Lantsukhay, Yuri, additional, Lazarev, Sergey Alexandrovich, additional, Lee, Lip Way, additional, Lifirenko, Igor Dmitrievich, additional, Martincic, Danko, additional, Matorin, Oleg Vladmirovhich, additional, McGrath, Margaret, additional, Misiukiewicz, Krzysztof, additional, Morris, John C., additional, Mufazalov, Fagim Fanisovich, additional, Niu, Jiaxin, additional, Pamoorthy Srinivasan, Devraj, additional, Perez Segura, Pedro, additional, Rauch, Daniel, additional, Ribeiro, Maria Leonor, additional, Rodriguez, Cristina, additional, Rolland, Frederic, additional, Russo, Antonio, additional, Ruzsa, Agnes, additional, Sanches, Frederico, additional, Shin, Sang-Won, additional, Shtiveland, Mikhail, additional, Soulieres, Denis, additional, Specenier, Pol, additional, Szekanecz, Eva, additional, Szota, Judit, additional, van Herpen, Carla M.L., additional, Velez-Cortes, Hector A., additional, Walsh, William V., additional, Wilop, Stefan, additional, Winterhalder, Ralph, additional, Wojtukiewicz, Marek, additional, Wong, Deborah, additional, and Zandberg, Dan, additional
- Published
- 2019
- Full Text
- View/download PDF
9. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
- Author
-
Mehanna, Hisham, primary, Robinson, Max, additional, Hartley, Andrew, additional, Kong, Anthony, additional, Foran, Bernadette, additional, Fulton-Lieuw, Tessa, additional, Dalby, Matthew, additional, Mistry, Pankaj, additional, Sen, Mehmet, additional, O'Toole, Lorcan, additional, Al Booz, Hoda, additional, Dyker, Karen, additional, Moleron, Rafael, additional, Whitaker, Stephen, additional, Brennan, Sinead, additional, Cook, Audrey, additional, Griffin, Matthew, additional, Aynsley, Eleanor, additional, Rolles, Martin, additional, De Winton, Emma, additional, Chan, Andrew, additional, Srinivasan, Devraj, additional, Nixon, Ioanna, additional, Grumett, Joanne, additional, Leemans, C René, additional, Buter, Jan, additional, Henderson, Julia, additional, Harrington, Kevin, additional, McConkey, Christopher, additional, Gray, Alastair, additional, Dunn, Janet, additional, McArdle, Orla, additional, Husband, David, additional, Loo, Vivienne, additional, Soe, Win, additional, Sridhar, Thiagarajan, additional, Jankowska, Petra, additional, Joseph, Mano, additional, Geropantas, Konstantinos, additional, Vaidya, Deepali, additional, Vijayan, Rengarajan, additional, Hwang, David, additional, Pettit, Laura, additional, Brennan, Sinéad, additional, Mendes, Ruheena, additional, Forster, Martin, additional, Evans, Mererid, additional, Foran, Bernie, additional, Nankivell, Paul, additional, Bryant, Jennifer, additional, Sharma, Neil, additional, Spruce, Rachel, additional, Brooks, Jill, additional, Batis, Nikos, additional, Roques, Tom, additional, Bidmead, Margaret, additional, Yang, Huiqi, additional, Nutting, Christopher, additional, Tyler, Justine, additional, Baines, Helen, additional, Gasnier, Anne, additional, Miles, Elizabeth, additional, and Clark, Catharine, additional
- Published
- 2019
- Full Text
- View/download PDF
10. Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004)
- Author
-
Nutting, Christopher M., primary, Morden, James P., additional, Beasley, Matthew, additional, Bhide, Shreerang, additional, Cook, Audrey, additional, De Winton, Emma, additional, Emson, Marie, additional, Evans, Mererid, additional, Fresco, Lydia, additional, Gollins, Simon, additional, Gujral, Dorothy, additional, Harrington, Kevin, additional, Joseph, Mano, additional, Lemon, Catherine, additional, Luxon, Linda, additional, van den Blink, Qurrat, additional, Mendes, Ruheena, additional, Miah, Aisha, additional, Newbold, Kate, additional, Prestwich, Robin, additional, Robinson, Martin, additional, Sanghera, Paul, additional, Simpson, Joanna, additional, Sivaramalingam, Muthiah, additional, Srihari, Narayanan Nair, additional, Sydenham, Mark, additional, Wells, Emma, additional, Witts, Stephanie, additional, and Hall, Emma, additional
- Published
- 2018
- Full Text
- View/download PDF
11. Ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Secondary analysis of efficacy and safety results of 4 dosing regimens in the phase II trial I4T-MC-JVDB.
- Author
-
Ajani, Jaffer A., primary, Udrea, Anghel Adrian, additional, Sarosiek, Tomasz, additional, Schenker, Michael, additional, Morgan, Carys, additional, Pikiel, Joanna, additional, Joseph, Mano, additional, Salek, Tomas, additional, Tournigand, Christophe, additional, Ferry, David Raymond, additional, Zhang, Yawei, additional, Long, Amanda, additional, Kuo, Wen-Ling, additional, Gao, Ling, additional, Russo, Francesca, additional, and Mansoor, Wasat, additional
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.